Xeris Biopharma (XERS) Financials

$4.71 +0.23 (+5.13%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$4.72 +0.01 (+0.21%)

As of 05/2/2025 06:53 PM Eastern

Annual Income Statements for Xeris Biopharma

This table shows Xeris Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-95	-62	-55
Consolidated Net Income / (Loss)	-95	-62	-55
Net Income / (Loss) Continuing Operations	-95	-62	-55
Total Pre-Tax Income	-96	-64	-57
Total Operating Income	-82	-44	-34
Total Gross Profit	88	135	166
Total Revenue	110	164	203
Operating Revenue	110	164	203
Total Cost of Revenue	23	29	37
Operating Cost of Revenue	23	29	37
Total Operating Expenses	170	179	200
Selling, General & Admin Expense	138	146	163
Research & Development Expense	21	22	26
Amortization Expense	11	11	11
Total Other Income / (Expense), net	-14	-19	-23
Interest Expense	15	29	33
Interest & Investment Income	2.58	4.75	5.32
Other Income / (Expense), net	-1.40	5.20	4.40
Income Tax Expense	-1.42	-1.25	-2.27
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.01	0.00	0.00
Basic Earnings per Share	($0.70)	($0.45)	($0.37)
Weighted Average Basic Shares Outstanding	135.63M	137.67M	146.77M
Diluted Earnings per Share	($0.70)	($0.45)	($0.37)
Weighted Average Diluted Shares Outstanding	135.63M	137.67M	146.77M
Weighted Average Basic & Diluted Shares Outstanding	137.29M	140.45M	153.94M

This table shows Xeris Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-22	-13	-17	-20	-12	-13	-19	-15	-16	-5.13
Consolidated Net Income / (Loss)	-22	-13	-17	-20	-12	-13	-19	-15	-16	-5.11
Net Income / (Loss) Continuing Operations	-22	-13	-17	-20	-12	-13	-19	-15	-16	-5.11
Total Pre-Tax Income	-22	-13	-17	-21	-13	-14	-19	-14	-19	-5.11
Total Operating Income	-19	-15	-13	-16	-4.91	-9.84	-14	-8.19	-13	1.68
Total Gross Profit	24	27	28	38	40	29	35	40	41	51
Total Revenue	30	33	33	38	48	44	41	48	54	60
Operating Revenue	30	33	33	38	48	44	41	48	54	60
Total Cost of Revenue	5.26	6.29	5.32	0.00	8.20	15	5.97	7.79	14	9.48
Operating Cost of Revenue	5.26	6.29	5.32	-	8.20	-	5.97	7.79	14	9.48
Total Operating Expenses	43	42	41	54	45	39	49	48	54	49
Selling, General & Admin Expense	34	34	34	38	37	38	38	40	45	40
Research & Development Expense	6.04	4.96	4.84	6.09	5.03	6.38	7.82	5.76	5.89	6.09
Amortization Expense	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71	2.71
Total Other Income / (Expense), net	-3.39	1.90	-3.56	-4.54	-7.61	-3.79	-4.43	-6.07	-6.17	-6.79
Interest Expense	3.99	4.37	6.22	6.53	9.68	7.02	9.72	7.96	7.79	7.70
Interest & Investment Income	0.47	1.84	1.30	1.22	1.12	1.11	1.92	1.29	1.20	0.91
Other Income / (Expense), net	0.13	4.43	1.36	0.77	0.95	2.13	3.37	0.60	0.42	0.00
Basic Earnings per Share	($0.16)	($0.10)	($0.12)	($0.14)	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)
Weighted Average Basic Shares Outstanding	135.95M	135.63M	137.14M	137.34M	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M
Diluted Earnings per Share	($0.16)	($0.10)	($0.12)	($0.14)	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)
Weighted Average Diluted Shares Outstanding	135.95M	135.63M	137.14M	137.34M	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M
Weighted Average Basic & Diluted Shares Outstanding	135.99M	137.29M	137.31M	138.07M	138.12M	140.45M	148.26M	149.00M	149.08M	153.94M

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	59	-55	4.07
Net Cash From Operating Activities	-103	-47	-37
Net Cash From Continuing Operating Activities	-103	-47	-37
Net Income / (Loss) Continuing Operations	-95	-62	-55
Consolidated Net Income / (Loss)	-95	-62	-55
Depreciation Expense	1.40	1.49	1.23
Amortization Expense	13	13	14
Non-Cash Adjustments To Reconcile Net Income	17	18	24
Changes in Operating Assets and Liabilities, net	-39	-17	-21
Net Cash From Investing Activities	34	-6.00	4.88
Net Cash From Continuing Investing Activities	34	-6.00	4.88
Purchase of Property, Plant & Equipment	-0.52	-2.26	-0.87
Purchase of Investments	0.00	-44	-34
Sale and/or Maturity of Investments	35	40	40
Net Cash From Financing Activities	127	-1.61	36
Net Cash From Continuing Financing Activities	127	-1.61	36
Repayment of Debt	-49	-1.19	-12
Issuance of Debt	146	0.00	50
Issuance of Common Equity	31	0.55	1.24
Other Financing Activities, net	-0.46	-0.98	-3.25
Cash Interest Paid	11	28	27

This table details how cash moves in and out of Xeris Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-11	42	-71	-4.74	-0.03	21	-4.76	-5.09	1.53	12
Net Cash From Operating Activities	-18	-16	-26	-14	-15	7.47	-20	-10	-8.31	1.98
Net Cash From Continuing Operating Activities	-18	-16	-26	-14	-15	7.47	-20	-10	-8.31	1.98
Net Income / (Loss) Continuing Operations	-22	-13	-17	-20	-12	-13	-19	-15	-16	-5.11
Consolidated Net Income / (Loss)	-22	-13	-17	-20	-12	-13	-19	-15	-16	-5.11
Depreciation Expense	0.36	0.37	0.36	0.39	0.39	0.35	0.33	0.28	0.31	0.31
Amortization Expense	3.17	3.62	2.98	3.11	3.23	3.29	3.28	3.38	3.43	3.57
Non-Cash Adjustments To Reconcile Net Income	9.40	-2.25	-0.68	3.64	12	3.32	1.97	6.25	5.48	10
Changes in Operating Assets and Liabilities, net	-9.05	-4.93	-12	-1.03	-18	14	-6.89	-5.26	-1.78	-7.05
Net Cash From Investing Activities	6.71	9.17	-44	8.45	15	15	-20	4.60	9.91	10
Net Cash From Continuing Investing Activities	6.71	9.17	-44	8.45	15	15	-20	4.60	9.91	10
Purchase of Property, Plant & Equipment	-0.18	-0.13	-0.24	-1.55	-0.35	-0.13	-0.16	-0.40	-0.09	-0.22
Sale and/or Maturity of Investments	6.89	9.30	0.00	10	15	15	5.00	10	15	10
Net Cash From Financing Activities	-0.19	49	-0.86	0.56	-0.07	-1.23	35	0.66	-0.08	0.40
Net Cash From Continuing Financing Activities	-0.19	49	-0.86	0.56	-0.07	-1.23	35	0.66	-0.08	0.40
Issuance of Common Equity	-	0.32	-	-	-	-	-	-	-	0.53
Other Financing Activities, net	-0.03	-0.02	-0.86	0.01	-0.07	-0.05	-2.98	-0.05	-0.08	-0.14
Cash Interest Paid	2.92	3.17	9.83	5.38	6.86	5.62	1.50	6.82	13	6.02

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	345	323	323
Total Current Assets	187	156	168
Cash & Equivalents	122	67	72
Short-Term Investments	0.00	5.00	0.00
Accounts Receivable	31	39	40
Inventories, net	25	39	48
Prepaid Expenses	9.29	5.78	7.45
Plant, Property, & Equipment, net	5.52	5.97	5.56
Total Noncurrent Assets	152	160	150
Goodwill	23	23	23
Intangible Assets	121	110	99
Other Noncurrent Operating Assets	8.72	28	28
Total Liabilities & Shareholders' Equity	345	323	323
Total Liabilities	299	329	353
Total Current Liabilities	74	95	100
Short-Term Debt	0.00	19	15
Accounts Payable	4.61	12	2.29
Accrued Expenses	65	60	76
Other Current Liabilities	4.24	4.66	7.17
Total Noncurrent Liabilities	226	234	252
Long-Term Debt	187	191	217
Noncurrent Deferred & Payable Income Tax Liabilities	3.52	2.27	0.00
Other Noncurrent Operating Liabilities	35	41	35
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	45	-6.78	-30
Total Preferred & Common Equity	45	-6.78	-30
Preferred Stock	0.00	0.00	0.00
Total Common Equity	45	-6.78	-30
Common Stock	600	610	642
Retained Earnings	-555	-617	-672
Accumulated Other Comprehensive Income / (Loss)	-0.02	-0.03	-0.03

This table presents Xeris Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	303	321	329	328	337	332	321
Total Current Assets	149	166	156	158	173	170	163
Cash & Equivalents	84	51	46	46	63	58	59
Short-Term Investments	9.32	44	34	20	25	20	10
Accounts Receivable	28	31	30	46	37	42	41
Inventories, net	20	29	37	38	41	43	45
Prepaid Expenses	7.85	11	8.31	7.97	7.64	7.36	7.14
Plant, Property, & Equipment, net	5.75	6.48	6.55	6.19	5.78	5.83	5.61
Total Noncurrent Assets	148	149	166	164	158	156	153
Goodwill	23	23	23	23	23	23	23
Intangible Assets	123	118	115	112	107	104	102
Other Noncurrent Operating Assets	2.17	8.62	28	28	28	28	28
Total Liabilities & Shareholders' Equity	303	321	329	328	337	332	321
Total Liabilities	248	291	315	324	346	351	349
Total Current Liabilities	69	81	80	87	73	75	91
Short-Term Debt	-	15	17	18	1.02	0.42	15
Accounts Payable	3.92	12	12	12	7.09	5.80	7.45
Accrued Expenses	64	50	48	54	37	40	62
Other Current Liabilities	0.34	4.21	3.65	3.49	28	30	6.72
Total Noncurrent Liabilities	179	210	235	237	273	276	258
Long-Term Debt	139	188	188	190	230	230	216
Noncurrent Deferred & Payable Income Tax Liabilities	3.86	3.52	2.84	2.50	2.58	3.32	0.00
Other Noncurrent Operating Liabilities	30	19	44	44	40	42	42
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	55	30	14	3.87	-9.18	-19	-28
Total Preferred & Common Equity	55	30	14	3.87	-9.18	-19	-28
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	55	30	14	3.87	-9.18	-19	-28
Common Stock	597	602	605	608	627	632	638
Retained Earnings	-542	-572	-591	-604	-636	-651	-667
Accumulated Other Comprehensive Income / (Loss)	-0.04	-0.03	-0.08	-0.05	-0.04	-0.03	-0.02

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	122.32%	48.68%	23.89%
EBITDA Growth	38.79%	64.15%	41.86%
EBIT Growth	28.07%	53.43%	24.63%
NOPAT Growth	28.84%	46.29%	23.55%
Net Income Growth	22.87%	34.23%	11.92%
EPS Growth	54.84%	35.71%	17.78%
Operating Cash Flow Growth	-7.70%	54.30%	21.36%
Free Cash Flow Firm Growth	50.26%	40.87%	53.98%
Invested Capital Growth	36.40%	18.60%	0.05%
Revenue Q/Q Growth	11.73%	7.37%	8.38%
EBITDA Q/Q Growth	37.36%	9.79%	40.16%
EBIT Q/Q Growth	31.50%	7.24%	24.31%
NOPAT Q/Q Growth	28.77%	10.80%	25.51%
Net Income Q/Q Growth	28.57%	-0.74%	13.11%
EPS Q/Q Growth	33.33%	0.00%	17.78%
Operating Cash Flow Q/Q Growth	11.08%	33.41%	-17.46%
Free Cash Flow Firm Q/Q Growth	0.00%	36.05%	-22.08%
Invested Capital Q/Q Growth	10.17%	-10.30%	-2.01%
Profitability Metrics	-	-	-
Gross Margin	79.47%	82.52%	81.86%
EBITDA Margin	-62.52%	-15.07%	-7.07%
Operating Margin	-74.32%	-26.85%	-16.57%
EBIT Margin	-75.59%	-23.68%	-14.40%
Profit (Net Income) Margin	-85.86%	-37.98%	-27.00%
Tax Burden Percent	98.52%	98.03%	96.03%
Interest Burden Percent	115.30%	163.63%	195.23%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-60.01%	-25.55%	-18.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-207.03%	-56.58%	-38.99%
Return on Net Nonoperating Assets (RNNOA)	-74.82%	-298.65%	319.32%
Return on Equity (ROE)	-134.83%	-324.20%	301.32%
Cash Return on Invested Capital (CROIC)	-90.80%	-42.57%	-18.05%
Operating Return on Assets (OROA)	-25.69%	-11.63%	-9.06%
Return on Assets (ROA)	-29.18%	-18.66%	-16.99%
Return on Common Equity (ROCE)	-134.83%	-324.20%	301.32%
Return on Equity Simple (ROE_SIMPLE)	-209.49%	917.94%	185.16%
Net Operating Profit after Tax (NOPAT)	-57	-31	-24
NOPAT Margin	-52.03%	-18.79%	-11.60%
Net Nonoperating Expense Percent (NNEP)	147.02%	31.03%	20.99%
Return On Investment Capital (ROIC_SIMPLE)	-24.70%	-15.16%	-11.63%
Cost of Revenue to Revenue	20.53%	17.48%	18.14%
SG&A Expenses to Revenue	124.94%	89.13%	80.50%
R&D to Revenue	19.02%	13.63%	12.59%
Operating Expenses to Revenue	153.79%	109.37%	98.43%
Earnings before Interest and Taxes (EBIT)	-83	-39	-29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-69	-25	-14
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.64	1.98	2.49
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.23	3.53	5.09
Enterprise Value to Revenue (EV/Rev)	2.23	2.82	3.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	4.14	-30.97	-7.84
Long-Term Debt to Equity	4.14	-28.15	-7.33
Financial Leverage	0.36	5.28	-8.19
Leverage Ratio	4.62	17.37	-17.74
Compound Leverage Factor	5.33	28.42	-34.63
Debt to Total Capital	80.54%	103.34%	114.63%
Short-Term Debt to Total Capital	0.00%	9.40%	7.46%
Long-Term Debt to Total Capital	80.54%	93.94%	107.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	19.46%	-3.34%	-14.63%
Debt to EBITDA	-2.71	-8.50	-16.16
Net Debt to EBITDA	-0.94	-5.57	-11.17
Long-Term Debt to EBITDA	-2.71	-7.73	-15.11
Debt to NOPAT	-3.26	-6.82	-9.86
Net Debt to NOPAT	-1.14	-4.47	-6.81
Long-Term Debt to NOPAT	-3.26	-6.20	-9.21
Altman Z-Score	-1.98	-1.75	-1.47
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.54	1.64	1.67
Quick Ratio	2.08	1.17	1.12
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-87	-51	-24
Operating Cash Flow to CapEx	-19,635.69%	-2,077.91%	-4,260.48%
Free Cash Flow to Firm to Interest Expense	-5.66	-1.74	-0.71
Operating Cash Flow to Interest Expense	-6.71	-1.60	-1.11
Operating Cash Flow Less CapEx to Interest Expense	-6.75	-1.67	-1.14
Efficiency Ratios	-	-	-
Asset Turnover	0.34	0.49	0.63
Accounts Receivable Turnover	4.57	4.68	5.10
Inventory Turnover	1.06	0.90	0.85
Fixed Asset Turnover	18.16	28.54	35.22
Accounts Payable Turnover	3.35	3.54	5.32
Days Sales Outstanding (DSO)	79.93	77.97	71.55
Days Inventory Outstanding (DIO)	345.53	405.03	431.14
Days Payable Outstanding (DPO)	109.09	103.03	68.65
Cash Conversion Cycle (CCC)	316.36	379.97	434.04
Capital & Investment Metrics	-	-	-
Invested Capital	110	131	131
Invested Capital Turnover	1.15	1.36	1.55
Increase / (Decrease) in Invested Capital	29	21	0.06
Enterprise Value (EV)	246	462	666
Market Capitalization	181	325	505
Book Value per Share	$0.33	($0.05)	($0.20)
Tangible Book Value per Share	($0.72)	($1.01)	($1.02)
Total Capital	232	203	202
Total Debt	187	210	232
Total Long-Term Debt	187	191	217
Net Debt	65	138	160
Capital Expenditures (CapEx)	0.52	2.26	0.87
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.77	7.73	11
Debt-free Net Working Capital (DFNWC)	113	80	82
Net Working Capital (NWC)	113	61	67
Net Nonoperating Expense (NNE)	37	31	31
Net Nonoperating Obligations (NNO)	65	138	160
Total Depreciation and Amortization (D&A)	14	14	15
Debt-free, Cash-free Net Working Capital to Revenue	-7.95%	4.72%	5.27%
Debt-free Net Working Capital to Revenue	102.67%	48.92%	40.54%
Net Working Capital to Revenue	102.67%	37.26%	33.10%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.70)	($0.45)	($0.37)
Adjusted Weighted Average Basic Shares Outstanding	135.63M	137.67M	146.77M
Adjusted Diluted Earnings per Share	($0.70)	($0.45)	($0.37)
Adjusted Weighted Average Diluted Shares Outstanding	135.63M	137.67M	146.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	137.29M	140.45M	153.94M
Normalized Net Operating Profit after Tax (NOPAT)	-57	-31	-24
Normalized NOPAT Margin	-52.03%	-18.79%	-11.60%
Pre Tax Income Margin	-87.15%	-38.74%	-28.12%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-5.44	-1.32	-0.88
NOPAT to Interest Expense	-3.74	-1.05	-0.71
EBIT Less CapEx to Interest Expense	-5.47	-1.39	-0.91
NOPAT Less CapEx to Interest Expense	-3.78	-1.12	-0.74
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Xeris Biopharma's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	168.76%	53.64%	50.39%	50.19%	62.56%	33.93%	22.42%	26.46%	12.31%	35.39%
EBITDA Growth	36.04%	85.89%	68.68%	40.44%	97.75%	39.69%	15.17%	66.55%	-2,462.46%	236.54%
EBIT Growth	23.17%	78.10%	61.14%	34.63%	78.75%	28.19%	8.76%	50.15%	-214.66%	121.78%
NOPAT Growth	22.90%	68.57%	54.33%	15.53%	73.84%	35.13%	-7.29%	48.76%	-162.43%	117.06%
Net Income Growth	16.06%	74.54%	50.07%	24.22%	44.17%	-3.56%	-12.75%	24.38%	-29.12%	61.81%
EPS Growth	58.97%	77.78%	52.00%	26.32%	43.75%	0.00%	-16.67%	28.57%	-22.22%	80.00%
Operating Cash Flow Growth	21.48%	44.31%	46.00%	33.31%	17.71%	146.35%	22.33%	24.71%	43.16%	-73.56%
Free Cash Flow Firm Growth	-476.50%	0.00%	63.31%	57.33%	55.74%	31.58%	85.27%	95.91%	106.60%	104.06%
Invested Capital Growth	4,425.95%	36.40%	34.90%	37.16%	45.66%	18.60%	-2.44%	-2.72%	-8.41%	0.05%
Revenue Q/Q Growth	17.46%	11.50%	0.16%	14.50%	27.13%	-8.13%	-8.45%	18.28%	12.91%	10.74%
EBITDA Q/Q Growth	23.13%	55.33%	-26.85%	-36.74%	97.09%	-1,095.01%	-78.43%	46.09%	-122.91%	163.68%
EBIT Q/Q Growth	19.84%	42.40%	-10.93%	-27.64%	73.94%	-94.63%	-40.95%	30.26%	-64.49%	113.47%
NOPAT Q/Q Growth	0.72%	19.22%	12.48%	-20.35%	69.25%	-100.31%	-44.75%	42.53%	-57.48%	113.02%
Net Income Q/Q Growth	16.63%	40.77%	-30.19%	-17.87%	38.57%	-9.85%	-41.75%	20.94%	-4.89%	67.51%
EPS Q/Q Growth	15.79%	37.50%	-20.00%	-16.67%	35.71%	-11.11%	-40.00%	28.57%	-10.00%	81.82%
Operating Cash Flow Q/Q Growth	13.85%	9.21%	-62.17%	47.42%	-6.30%	151.14%	-371.76%	49.03%	19.74%	123.78%
Free Cash Flow Firm Q/Q Growth	2.33%	63.93%	-12.05%	-8.12%	-1.31%	44.26%	75.88%	69.95%	263.45%	-65.76%
Invested Capital Q/Q Growth	-0.34%	10.17%	24.69%	0.19%	5.83%	-10.30%	2.57%	-0.09%	-0.36%	-2.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	82.30%	81.02%	83.98%	100.00%	83.03%	65.93%	85.31%	83.79%	74.95%	84.23%
EBITDA Margin	-50.88%	-20.39%	-25.82%	-30.84%	-0.71%	-9.18%	-17.89%	-8.16%	-16.10%	9.26%
Operating Margin	-63.18%	-45.77%	-40.00%	-42.04%	-10.17%	-22.17%	-35.05%	-17.03%	-23.76%	2.79%
EBIT Margin	-62.75%	-32.42%	-35.90%	-40.02%	-8.20%	-17.38%	-26.76%	-15.78%	-22.98%	2.80%
Profit (Net Income) Margin	-73.44%	-39.01%	-50.71%	-52.20%	-25.23%	-30.16%	-46.71%	-31.22%	-29.00%	-8.51%
Tax Burden Percent	98.47%	97.45%	100.00%	96.71%	97.30%	98.27%	101.64%	105.25%	82.56%	100.00%
Interest Burden Percent	118.85%	123.49%	141.25%	134.87%	316.02%	176.62%	171.72%	188.00%	152.83%	-304.35%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-85.30%	-36.96%	-28.38%	-33.12%	-8.84%	-21.10%	-30.95%	-15.91%	-22.31%	3.04%
ROIC Less NNEP Spread (ROIC-NNEP)	-120.21%	-46.06%	-41.73%	-44.61%	-18.19%	-27.52%	-38.13%	-22.60%	-26.72%	-1.18%
Return on Net Nonoperating Assets (RNNOA)	-113.74%	-16.65%	-37.26%	-76.75%	-57.77%	-145.22%	-458.31%	1,110.84%	332.00%	9.70%
Return on Equity (ROE)	-199.04%	-53.60%	-65.64%	-109.87%	-66.60%	-166.32%	-489.26%	1,094.93%	309.69%	12.73%
Cash Return on Invested Capital (CROIC)	0.00%	-90.80%	-68.38%	-68.48%	-65.26%	-42.57%	-20.70%	-16.40%	-13.85%	-18.05%
Operating Return on Assets (OROA)	-28.52%	-11.02%	-13.22%	-16.58%	-3.97%	-8.54%	-13.94%	-8.67%	-13.27%	1.76%
Return on Assets (ROA)	-33.38%	-13.26%	-18.68%	-21.62%	-12.21%	-14.82%	-24.33%	-17.15%	-16.75%	-5.35%
Return on Common Equity (ROCE)	-199.04%	-53.60%	-65.64%	-109.87%	-66.60%	-166.32%	-489.26%	1,094.93%	309.69%	12.73%
Return on Equity Simple (ROE_SIMPLE)	-240.77%	0.00%	-258.85%	-523.69%	-1,598.84%	0.00%	701.69%	308.85%	222.83%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-11	-9.29	-11	-3.44	-6.89	-9.97	-5.73	-9.03	1.18
NOPAT Margin	-44.23%	-32.04%	-28.00%	-29.43%	-7.12%	-15.52%	-24.54%	-11.92%	-16.63%	1.96%
Net Nonoperating Expense Percent (NNEP)	34.92%	9.11%	13.35%	11.49%	9.36%	6.41%	7.18%	6.68%	4.42%	4.22%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.57%	-	-	-	-3.39%	-	-	-	0.58%
Cost of Revenue to Revenue	17.70%	18.98%	16.02%	0.00%	16.97%	34.07%	14.69%	16.21%	25.05%	15.77%
SG&A Expenses to Revenue	116.03%	103.66%	101.23%	99.02%	77.17%	84.63%	94.44%	83.21%	82.86%	66.79%
R&D to Revenue	20.33%	14.95%	14.57%	16.02%	10.42%	14.38%	19.25%	11.98%	10.85%	10.14%
Operating Expenses to Revenue	145.48%	126.79%	123.97%	142.04%	93.20%	88.10%	120.36%	100.83%	98.71%	81.44%
Earnings before Interest and Taxes (EBIT)	-19	-11	-12	-15	-3.96	-7.72	-11	-7.58	-12	1.68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-6.76	-8.57	-12	-0.34	-4.08	-7.27	-3.92	-8.74	5.56
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.85	4.00	7.45	26.37	66.44	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.15	1.64	1.84	2.68	1.68	1.98	1.81	1.84	2.27	2.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.57	2.23	2.41	3.51	2.73	3.53	3.38	3.63	4.39	5.09
Enterprise Value to Revenue (EV/Rev)	2.61	2.23	2.73	3.61	2.61	2.82	2.65	2.68	3.13	3.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.52	4.14	6.74	15.02	53.80	-30.97	-25.14	-11.97	-8.17	-7.84
Long-Term Debt to Equity	2.52	4.14	6.24	13.80	49.27	-28.15	-25.02	-11.95	-7.63	-7.33
Financial Leverage	0.95	0.36	0.89	1.72	3.18	5.28	12.02	-49.16	-12.42	-8.19
Leverage Ratio	8.26	4.62	5.21	7.39	10.71	17.37	31.53	-117.01	-26.53	-17.74
Compound Leverage Factor	9.82	5.71	7.36	9.97	33.84	30.68	54.14	-219.97	-40.55	53.99
Debt to Total Capital	71.56%	80.54%	87.08%	93.76%	98.18%	103.34%	104.14%	109.11%	113.95%	114.63%
Short-Term Debt to Total Capital	0.00%	0.00%	6.43%	7.62%	8.27%	9.40%	0.46%	0.20%	7.42%	7.46%
Long-Term Debt to Total Capital	71.56%	80.54%	80.65%	86.14%	89.90%	93.94%	103.68%	108.92%	106.54%	107.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	28.44%	19.46%	12.92%	6.24%	1.82%	-3.34%	-4.14%	-9.11%	-13.95%	-14.63%
Debt to EBITDA	-1.26	-2.71	-4.04	-4.86	-7.59	-8.50	-9.86	-14.79	-9.64	-16.16
Net Debt to EBITDA	-0.41	-0.94	-2.14	-2.94	-5.18	-5.57	-6.12	-9.82	-6.74	-11.17
Long-Term Debt to EBITDA	-1.26	-2.71	-3.74	-4.46	-6.95	-7.73	-9.81	-14.77	-9.01	-15.11
Debt to NOPAT	-1.72	-3.26	-4.38	-4.63	-6.02	-6.82	-7.33	-8.87	-7.32	-9.86
Net Debt to NOPAT	-0.56	-1.14	-2.32	-2.81	-4.11	-4.47	-4.55	-5.89	-5.12	-6.81
Long-Term Debt to NOPAT	-1.72	-3.26	-4.05	-4.25	-5.51	-6.20	-7.29	-8.85	-6.84	-9.21
Altman Z-Score	-1.55	-1.28	-1.46	-1.30	-1.42	-1.43	-1.35	-1.36	-1.45	-1.16
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.17	2.54	2.03	1.95	1.82	1.64	2.37	2.26	1.79	1.67
Quick Ratio	1.76	2.08	1.55	1.39	1.29	1.17	1.71	1.59	1.21	1.12
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-111	-40	-45	-49	-49	-27	-6.61	-1.99	3.25	1.11
Operating Cash Flow to CapEx	-10,087.50%	-12,211.36%	-10,983.19%	-887.86%	-4,234.78%	5,659.85%	-12,379.88%	-2,606.55%	-9,545.98%	897.73%
Free Cash Flow to Firm to Interest Expense	-27.84	-9.17	-7.22	-7.43	-5.08	-3.90	-0.68	-0.25	0.42	0.14
Operating Cash Flow to Interest Expense	-4.45	-3.69	-4.21	-2.11	-1.51	1.06	-2.09	-1.30	-1.07	0.26
Operating Cash Flow Less CapEx to Interest Expense	-4.49	-3.72	-4.24	-2.34	-1.54	1.05	-2.11	-1.35	-1.08	0.23
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.34	0.37	0.41	0.48	0.49	0.52	0.55	0.58	0.63
Accounts Receivable Turnover	4.80	4.57	4.48	4.79	4.16	4.68	5.02	4.99	4.30	5.10
Inventory Turnover	1.24	1.06	0.94	0.62	0.68	0.90	0.84	0.93	1.02	0.85
Fixed Asset Turnover	15.87	18.16	19.01	21.08	25.58	28.54	27.95	29.30	31.76	35.22
Accounts Payable Turnover	5.21	3.35	1.88	1.85	2.48	3.54	3.07	4.26	4.35	5.32
Days Sales Outstanding (DSO)	75.97	79.93	81.56	76.20	87.84	77.97	72.71	73.10	84.84	71.55
Days Inventory Outstanding (DIO)	293.37	345.53	386.47	588.77	536.73	405.03	435.53	391.28	357.71	431.14
Days Payable Outstanding (DPO)	70.06	109.09	194.23	197.45	147.34	103.03	118.84	85.72	83.90	68.65
Cash Conversion Cycle (CCC)	299.28	316.36	273.80	467.52	477.24	379.97	389.41	378.67	358.66	434.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	100	110	138	138	146	131	134	134	134	131
Invested Capital Turnover	1.93	1.15	1.01	1.13	1.24	1.36	1.26	1.33	1.34	1.55
Increase / (Decrease) in Invested Capital	98	29	36	37	46	21	-3.36	-3.75	-12	0.06
Enterprise Value (EV)	257	246	331	484	399	462	454	487	587	666
Market Capitalization	212	181	224	360	257	325	310	334	425	505
Book Value per Share	$0.40	$0.33	$0.22	$0.10	$0.03	($0.05)	($0.07)	($0.13)	($0.19)	($0.20)
Tangible Book Value per Share	($0.67)	($0.72)	($0.81)	($0.91)	($0.95)	($1.01)	($0.99)	($0.99)	($1.03)	($1.02)
Total Capital	194	232	233	218	212	203	222	212	203	202
Total Debt	139	187	203	205	208	210	231	231	231	232
Total Long-Term Debt	139	187	188	188	190	191	230	230	216	217
Net Debt	45	65	107	124	142	138	143	153	162	160
Capital Expenditures (CapEx)	0.18	0.13	0.24	1.55	0.35	0.13	0.16	0.40	0.09	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-8.77	3.95	12	23	7.73	14	18	17	11
Debt-free Net Working Capital (DFNWC)	80	113	99	93	89	80	101	95	87	82
Net Working Capital (NWC)	80	113	84	76	71	61	100	95	72	67
Net Nonoperating Expense (NNE)	8.69	2.31	7.54	8.66	8.75	6.50	9.01	9.27	6.71	6.29
Net Nonoperating Obligations (NNO)	45	65	107	124	142	138	143	153	162	160
Total Depreciation and Amortization (D&A)	3.53	3.99	3.35	3.49	3.62	3.64	3.60	3.66	3.74	3.88
Debt-free, Cash-free Net Working Capital to Revenue	-13.25%	-7.95%	3.25%	8.97%	14.77%	4.72%	8.09%	9.76%	9.31%	5.27%
Debt-free Net Working Capital to Revenue	81.44%	102.67%	81.61%	69.14%	57.99%	48.92%	59.07%	52.52%	46.35%	40.54%
Net Working Capital to Revenue	81.44%	102.67%	69.28%	56.73%	46.51%	37.26%	58.47%	52.29%	38.31%	33.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.16)	($0.10)	($0.12)	($0.14)	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)
Adjusted Weighted Average Basic Shares Outstanding	135.95M	135.63M	137.14M	137.34M	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M
Adjusted Diluted Earnings per Share	($0.16)	($0.10)	($0.12)	($0.14)	($0.09)	($0.10)	($0.14)	($0.10)	($0.11)	($0.02)
Adjusted Weighted Average Diluted Shares Outstanding	135.95M	135.63M	137.14M	137.34M	138.06M	137.67M	140.51M	148.35M	148.99M	146.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	135.99M	137.29M	137.31M	138.07M	138.12M	140.45M	148.26M	149.00M	149.08M	153.94M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-11	-9.29	-11	-3.44	-6.89	-9.97	-5.73	-9.03	1.18
Normalized NOPAT Margin	-44.23%	-32.04%	-28.00%	-29.43%	-7.12%	-15.52%	-24.54%	-11.92%	-16.63%	1.96%
Pre Tax Income Margin	-74.58%	-40.03%	-50.71%	-53.98%	-25.93%	-30.70%	-45.95%	-29.66%	-35.13%	-8.51%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.68	-2.46	-1.92	-2.33	-0.41	-1.10	-1.12	-0.95	-1.60	0.22
NOPAT to Interest Expense	-3.30	-2.43	-1.50	-1.71	-0.36	-0.98	-1.03	-0.72	-1.16	0.15
EBIT Less CapEx to Interest Expense	-4.72	-2.49	-1.96	-2.57	-0.45	-1.12	-1.14	-1.00	-1.61	0.19
NOPAT Less CapEx to Interest Expense	-3.34	-2.46	-1.53	-1.95	-0.39	-1.00	-1.04	-0.77	-1.17	0.12
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Xeris Biopharma's Financials

When does Xeris Biopharma's fiscal year end?

According to the most recent income statement we have on file, Xeris Biopharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Xeris Biopharma's net income changed over the last 2 years?

Xeris Biopharma's net income appears to be on a downward trend, with a most recent value of -$54.84 million in 2024, falling from -$94.66 million in 2022. The previous period was -$62.26 million in 2023. Find out what analysts predict for Xeris Biopharma in the coming months.

What is Xeris Biopharma's operating income?

Xeris Biopharma's total operating income in 2024 was -$33.65 million, based on the following breakdown:

Total Gross Profit: $166.24 million
Total Operating Expenses: $199.88 million

How has Xeris Biopharma revenue changed over the last 2 years?

Over the last 2 years, Xeris Biopharma's total revenue changed from $110.25 million in 2022 to $203.07 million in 2024, a change of 84.2%.

How much debt does Xeris Biopharma have?

Xeris Biopharma's total liabilities were at $352.68 million at the end of 2024, a 7.1% increase from 2023, and a 17.8% increase since 2022.

How much cash does Xeris Biopharma have?

In the past 2 years, Xeris Biopharma's cash and equivalents has ranged from $67.45 million in 2023 to $121.97 million in 2022, and is currently $71.62 million as of their latest financial filing in 2024.

How has Xeris Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Xeris Biopharma's book value per share changed from 0.33 in 2022 to -0.20 in 2024, a change of -159.8%.

Related Companies

This page (NASDAQ:XERS) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Financials

Frequently Asked Questions About Xeris Biopharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Financials

Annual Income Statements for Xeris Biopharma

Quarterly Income Statements for Xeris Biopharma

Annual Cash Flow Statements for Xeris Biopharma

Quarterly Cash Flow Statements for Xeris Biopharma

Annual Balance Sheets for Xeris Biopharma

Quarterly Balance Sheets for Xeris Biopharma

Annual Metrics and Ratios for Xeris Biopharma

Quarterly Metrics and Ratios for Xeris Biopharma

Frequently Asked Questions About Xeris Biopharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools